EXPRESS MAILING NO.: **EL615211957US**

HOWREY SIMON ARNOLD & WHITE, LLP
301 Ravenswood Avenue
Box 34
Menlo Park, CA 94025
(650) 463-8109

FORM PTO-1083
Box:
THE COMMISSIONER FOR PATENTS
Washington, D.C. 20231

Attorney Docket No.00800.0051.CNUS03

Sir:

In re application of: Emil D. KAKKIS
Application Serial No. 09/993,241
Filed: November 13, 2001
For: METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF RECOMBINANT α-L-IDURONIDASE

Transmitted herewith are the following:

1. PTO Form 1083;
2. Preliminary Amendment;
3. Clean Version with Amendments Incorporated;
4. Marked-up Version to Show Changes Made;
5. Check in the amount of $321.00; and
6. Return receipt postcard.

___ No Additional Claim Fee is required.

The claim fee has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)	SMALL ENTITY			OTHER THAN A SMALL ENTITY	
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Addit. Fee	Or	Rate	Addit. Fee
Total Claims	57	MINUS	26	= 31	x 9 =	$ 279.00		x 18 =	$ 00.00
Indep. Claims	4	MINUS	3	= 1	X 42 =	$ 42.00		x 84 =	$ 00.00
☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM					+135 =	$ .00		+ 270 =	$ 00.00
					Total Addit. Fee	$ 321.00	Or	TOTAL	$ 00.00

xx The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3038 referencing Attorney Docket No.: 00800.0051.00US00.

Date: **October 2, 2002**

Albert P. Halluin (Reg. No. 25,227)
Robin C. Chiang (Reg. No. 46,619)

EXPRESS MAILING NO.: EL615211957US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Emil D. KAKKIS

Application No.: 09/993,241

Filed: November 13, 2001

For: **METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF RECOMBINANT α-L-IDURONIDASE**

Art Unit: 1652

Examiner: Not yet assigned

Attorney Docket No: 00800.0051.CNUS03

9/B
10/15/02

PRELIMINARY AMENDMENT

Director of the U.S. Patent and Trademark Office
Washington, D.C. 20231

Sir:

AMENDMENT

In the Claims:

Claims 19, 21, 22, 24, 26 and 28 as amended follows:.

B1 19. (Amended) The method of Claim 14 wherein the disease is mucopolysaccharidosis I.

21. (Amended) The method of Claim 14 wherein said human subject suffering from the disease demonstrates about 1% or less of a normal α-L-iduronidase activity.

B2 22. (Amended) The method of Claim 14 wherein a dose of at least about 100 units per kilogram said human recombinant α-L-iduronidase is administered weekly to said human subject suffering from said deficiency.

B3 24. (Amended) The method of Claim 14 wherein said administering is a slow infusion of at least 0.5 mg/kg of said formulation for about an hour, followed by a rapid two-hour infusion rate.